Ponego Ponatshego
A5051354157- HIV-related health complications and treatments
- Fungal Infections and Studies
- HIV/AIDS Research and Interventions
- Antifungal resistance and susceptibility
- Nail Diseases and Treatments
- HIV/AIDS drug development and treatment
- Health Policy Implementation Science
- Pharmacological Effects and Toxicity Studies
- Pregnancy and Medication Impact
- Pneumocystis jirovecii pneumonia detection and treatment
- Primary Care and Health Outcomes
- Lipoproteins and Cardiovascular Health
- Frailty in Older Adults
- Chronic Kidney Disease and Diabetes
- Infective Endocarditis Diagnosis and Management
- HIV Research and Treatment
- Gestational Diabetes Research and Management
- Global Maternal and Child Health
- Nutrition and Health in Aging
- Infectious Diseases and Tuberculosis
- Phytoplasmas and Hemiptera pathogens
- Maternal Mental Health During Pregnancy and Postpartum
- Health Systems, Economic Evaluations, Quality of Life
- Bacterial Infections and Vaccines
- Neurological and metabolic disorders
Botswana Harvard AIDS Institute Partnership
2019-2025
University of Botswana
2024
National Health Laboratory Service
2020
Abstract Background We evaluated associations between antepartum weight change and adverse pregnancy outcomes antiretroviral therapy (ART) regimens week 50 postpartum body mass index in IMPAACT 2010. Methods Women with human immunodeficiency virus (HIV)-1 9 countries were randomized 1:1:1 at 14–28 weeks’ gestational age (GA) to start dolutegravir (DTG) + emtricitabine (FTC)/tenofovir alafenamide fumarate (TAF) versus DTG FTC/tenofovir disoproxil (TDF) efavirenz (EFV)/FTC/TDF. Insufficient...
BackgroundHIV-associated cryptococcal meningitis is the second leading cause of AIDS-related deaths, with a 10-week mortality rate 25–30%. Fungal load assessed by colony-forming unit (CFU) counts used as prognostic marker and to monitor response treatment in research studies. PCR-based assessment fungal could be quicker less labour-intensive. We sought design, optimise, validate quantitative PCR (qPCR) assays for detection, identification, quantification Cryptococcus infections patients...
Safe and potent antiretroviral medications in child-friendly formulations are needed to treat young children living with HIV-1. We aimed select dosing for a dispersible tablet formulation of dolutegravir that achieved pharmacokinetic exposures similar those adults, was safe well tolerated children.International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) P1093 is phase 1-2 ongoing multicentre, open-label, non-comparative study dolutegravir. A 5 mg studied aged 4 weeks less...
HIV-associated cryptococcal meningitis is a leading cause of AIDS-related mortality. The AMBITION-cm trial showed that regimen based on single high dose liposomal amphotericin B deoxycholate (AmBisome group) was non-inferior to the WHO-recommended treatment seven daily doses (control and associated with fewer adverse events. We present five-country cost-effectiveness analysis.
People living with HIV (PLWH) in sub-Saharan Africa are vulnerable to end organ dysfunction such as albuminuria, which is associated an increased risk of cardiovascular and renal events. However, the prevalence persistent albuminuria among PLWH unclear. This observational prospective study assessed for persistence a cohort on longterm antiretroviral therapy (ART) across various service platforms Gaborone, Botswana. A subgroup ART treated (n = 867) from larger cross-sectional 1537) assessing...
<ns4:p><ns4:bold>Background: </ns4:bold>Cryptococcal antigen (CrAg) screening for antiretroviral therapy (ART)-naïve adults with advanced HIV/AIDS can reduce the incidence of cryptococcal meningitis (CM) and all-cause mortality. We modeled cost-effectiveness laboratory-based “reflex” CrAg ART-naïve CrAg-positive patients CD4<100 cells/µL (those currently targeted in guidelines) ART-experienced (who make up an increasingly large proportion individuals HIV/AIDS).</ns4:p><ns4:p>...
Abstract Background Botswana serves as a model of success for HIV with 95% people living (PLWH) virally suppressed. Yet, only 19% PLWH and hypertension have controlled blood pressure. To address this gap, InterCARE, care that integrates through a) provider training; b) adapted electronic health record; c) treatment partners (peer support), was designed. This study presents results from our baseline assessment the determinants factors used to guide adaptations InterCARE implementation...
Abstract Chronic HIV disease is associated with a fivefold increase in albuminuria outside of sub-Saharan Africa. However, very little known about risk among people living (PLWH) Therefore, we conducted cross-sectional observational clinic-based study 1533 adults aged 21 years or older between January 2020 and 2021 Gaborone, Botswana. Clinical was defined using sex-based albumin‒creatinine ratio (ACR) 25–355 mg/g for females 17–250 males. The population mean age 48.5 (SD 10.3) years,...
Abstract Background The role of computed tomography (CT) before lumbar puncture (LP) is unclear, with limited evidence for a causal link between LP and cerebral herniation or the ability CT to identify individuals at risk herniation. risks delay deferral are potentially greater in high–HIV prevalence, resource-limited settings; we analyzed data from such setting determine impact on time treatment, as well mortality. Methods Adults suspected central nervous system (CNS) infection were...
Background: Cryptococcal antigen (CrAg) screening for antiretroviral therapy (ART)-naïve adults with advanced HIV/AIDS can reduce the incidence of cryptococcal meningitis (CM) and all-cause mortality. We modeled cost-effectiveness laboratory-based "reflex" CrAg ART-naïve CrAg-positive patients CD4<100 cells/µL (those currently targeted in guidelines) ART-experienced (who make up an increasingly large proportion individuals HIV/AIDS). Methods: A decision analytic model was developed to...
Abstract Background We sought to explore multinational differences in functional status by global burden of disease (GBD) regions the REPRIEVE cohort. Methods is a prospective, double-blind, randomized, placebo-controlled, multicenter, phase III primary cardiovascular prevention study pitavastatin calcium vs placebo among people with human immunodeficiency virus (HIV, PWH) ages 40–75 on antiretroviral therapy (ART). GBD super were defined using World Health Organization classifications....
Introduction Cryptococcal meningitis is responsible for around 15% of all HIV-related deaths globally. Conventional treatment courses with amphotericin B require prolonged hospitalisation and are associated multiple toxicities poor outcomes. A phase II study has shown that a single high dose liposomal may be comparable to standard treatment. We propose III clinical endpoint trial comparing single, high-dose the WHO recommended first-line at six sites across five counties. An economic...
<title>Abstract</title> This work aims to evaluate associations between self-reported sleep health and frailty in Botswana, a sub-Saharan Africa setting. Fifty persons living with HIV (PLWH) on suppressive antiretroviral therapy (ART) fifty seronegative control participants are enrolled Botswana. Sleep quality is scored subjectively as “good” or “poor” based self-report. A index (FI) constructed thirty-three deficits related body mass index, waist circumference, physical activity, emotional...
Abstract Background Successful HIV treatment programs have turned into a chronic condition, but noncommunicable diseases such as hypertension jeopardize this progress. Hypertension control rates among people with (PWH) are low owing to gaps in patient awareness, diagnosis, effective treatment, and management of both conditions at separate clinic visits. Integrated management, our study, InterCARE, can enhance HIV-hypertension integration blood pressure (BP) control. Methods Our pilot study...
Abstract Background Despite success in HIV treatment, diagnosis and management of hypertension (HTN) cardiovascular disease (CVD) remains suboptimal among people living with (PLWH) Botswana, an overall HTN control only 19% compared to 98% viral suppressed. These gaps persist despite CVD primary care national guidelines availability free healthcare including antihypertensive medications. Our study aims develop test strategies close the gap PLWH, through integration into care, leveraging...
Abstract Background This exploratory analysis investigates the prevalence and risk factors of neurocognitive toxicity in postpartum women on HIV treatment response to a concern an Isoniazid Preventive Therapy (IPT)/Efavirenz interaction. Trial Design Pregnant from countries with high TB were randomized IMPAACT P1078 28 weeks IPT started either during pregnancy or at 12 postpartum. Partway through study implementation, Patient Health Questionnaire 9, cognitive complaint questionnaire,...
<ns4:p><ns4:bold>Background: </ns4:bold>Cryptococcal antigen (CrAg) screening in individuals with advanced HIV reduces cryptococcal meningitis (CM) cases and deaths. The World Health Organization recently recommended increasing thresholds from CD4 ≤100 cells/µL to ≤200 cells/µL. CrAg at is cost-effective; however, the cost-effectiveness of patients 101–200 requires evaluation.</ns4:p><ns4:p> <ns4:bold>Methods: </ns4:bold>Using a decision analytic model Botswana-specific cost clinical...
Abstract Introduction The aim of this proof-of-concept study is to explore sleep health disparity and associations with frailty in middle-aged (i.e., age&lt; 65 years) people living HIV (PLWH) an African setting. Methods Data were from 98 participants (age: 56.8±4.3 [mean±SD] years; female: 49 [50%]) enrolled Botswana, Africa, between March-December 2021. Forty-eight seropositive PLWH) on suppressive antiretroviral therapy regimens; 50 confirmed uninfected controls). PLWH controls...
<ns3:p><ns3:bold>Background: </ns3:bold>Cryptococcal antigen (CrAg) screening in individuals with advanced HIV reduces cryptococcal meningitis (CM) cases and deaths. The World Health Organization recently recommended increasing thresholds from CD4 ≤100 cells/µL to ≤200 cells/µL. CrAg at is cost-effective; however, the cost-effectiveness of patients 101–200 requires evaluation.</ns3:p><ns3:p> <ns3:bold>Methods: </ns3:bold>Using a decision analytic model Botswana-specific cost clinical...